Nash News Banner Xl

International NASH Day is one week away!

NASH 2023 Banner 1

How do you plan to #StepUpforNASH? Check out our toolkit, join the conversation on social media and make sure to use #NASHday and #StepUpforNASH.

GLI & NASH Advocates Address the Importance of Real-World Impact: FDA GIDAC Rejects NASH Treatment, Sparking Concerns


On May 19, the FDA’s Gastrointestinal Drugs Advisory Committee (GIDAC) rejected Intercept Pharmaceutical’s application for obeticholic acid (OCA) as a treatment for NASH, despite meeting the FDA’s endpoint of reducing fibrosis. The FDA’s GIDAC failed to recognize the urgent need for NASH treatments and disregarded the real-world impact on patients. Patient advocates call for a reorganization of FDA committees and divisions to prioritize patient outcomes and ensure a consistent, evidence-based regulatory process. Read more.

Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey


An article co-authored by Global Liver Institute revealed that although primary care doctors often treat NASH patients as their first point of contact, only a small percentage do so accurately. Many primary care doctors are unaware of guidelines for NASH diagnosis and management, highlighting the need for increased awareness. However, other physicians recognize the potential role of primary care doctors in supporting patients with lifestyle changes, weight loss, and managing related conditions.

Navigating Nutrition – Innovating for Better Health in Chronic Diseases


Jeff McIntyre, GLI’s VP of Liver Health Programs, chaired a panel at the Tufts University’s Friedman School of Nutrition, Food & Nutrition Innovation Council’s recent meeting. The panel, “Can We Innovate with Human Studies to Demonstrate Health Benefits?” discussed the perspective of how those with chronic disease can be better addressed in clinical trials around nutrition. The panel featured Noah Craft MD, PhD, of People Science; Diedre Tobias, PhD, of Harvard T.H. Chan School of Public Health; Jeffrey Blumberg, PhD, Professor Emeritus, Tufts University; and Jan-Willem van Klinken, MD, PhD, Senior Vice President Medical, Scientific & Regulatory Affairs at Brightseed Bioactives.

Upcoming events:

To learn more about the NASH Council or become a member, please visit or reach out to